Managing tyrosine kinase inhibitors side effects in thyroid cancer

References

• Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer. 1998;83(12):2638–2648. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874472. Accessed September 9, 2013. ​ ​
   PubMed Web of Science ®Google Scholar
• Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110(7):1451–1456. DOI:10.1002/cncr.22956
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22(9):884–889. DOI:10.1089/thy.2011.0535
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7977430. Accessed September 9, 2013.
   PubMed Web of Science ®Google Scholar
• Jarząb B, Dedecjus M, Handkiewicz-Junak D, et al. Diagnostics and treatment of thyroid carcinoma. Endokrynol Pol. 2016;67(1):74–107. DOI:10.5603/EP.2016.0011
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. DOI:10.1089/thy.2015.0020
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899. DOI:10.1210/jc.2005-2838
   PubMed Web of Science ®Google Scholar
• Massicotte M-H, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol. 2014;170(4):575–582. DOI:10.1530/EJE-13-0825
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–2142. DOI:10.1002/cncr.22244
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014;12(12):1671–1680. quiz 1680. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25505208. Accessed July 28, 2015.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612. DOI:10.1089/thy.2008.0403
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Bastholt L, Dralle H, et al. European Thyroid Association Guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1(1):5–14. DOI:10.1159/000336977
   PubMedGoogle Scholar
• Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015;6:176. DOI:10.3389/fendo.2015.00176
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–328. DOI:10.1016/S0140-6736(14)60421-9
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630. DOI:10.1056/NEJMoa1406470
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141. DOI:10.1200/JCO.2011.35.5040
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. DOI:10.1200/JCO.2012.48.4659
   PubMed Web of Science ®Google Scholar
• Brose M, Jarzab B, Elisei R, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer treated with sorafenib on phase 3 DECISION trial (ABSTRACT). J Clin Oncol. 2014;32(15(Suppl)):6060.
   Web of Science ®Google Scholar
• Brose M, Schlumberger M, Tahara M, et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. J Clin Oncol. 2015;suppl(33):abstr 6048.
   Google Scholar
• Schlumberger M, Elisei R, Muller S, et al. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients with documented RECIST progression at baseline. J Clin Oncol. 2015;33:6012.
   Web of Science ®Google Scholar
• Sherman S, Elisei R, Mueller S, et al. The impact of RET and RAS mutation status on overall survival in the EXAM trial, a phase 3 study of cabozantinib in patients with progressive, metastatic medullary thyroid cancer (MTC). In: ITC annual meeting. Orlando, Florida: Lake Buena Vista; 2015 Oct 18–23. ​
   Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795. DOI:10.1038/sj.bjc.6603813
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–4719. DOI:10.1200/JCO.2008.16.3279
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, M V K, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–1684. DOI:10.1200/JCO.2008.18.2717
   PubMed Web of Science ®Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165(2):315–322. DOI:10.1530/EJE-11-0129
   PubMed Web of Science ®Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012;19(2):209–216. DOI:10.1530/ERC-11-0351
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923–931. DOI:10.1530/EJE-09-0702
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015;121:2749–2756. DOI:10.1002/cncr.29395
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res. 2016;22(1):44–53. DOI:10.1158/1078-0432.CCR-15-1127
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, et al. (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95(6):2664–2671. DOI:10.1210/jc.2009-2461
   PubMed Web of Science ®Google Scholar
• Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772. DOI:10.1200/JCO.2009.23.6604
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666. DOI:10.1200/JCO.2010.32.4145
   PubMed Web of Science ®Google Scholar
• Klein Hesselink EN, Steenvoorden D, Kapiteijn E, et al. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2015;172(5):R215–25. DOI:10.1530/EJE-14-0788
   PubMed Web of Science ®Google Scholar
• Schutz FAB, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30(8):871–877. DOI:10.1200/JCO.2011.37.1195
   PubMed Web of Science ®Google Scholar
• Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31(32):4046–4053. DOI:10.1200/JCO.2013.49.1043
   PubMed Web of Science ®Google Scholar
• Yang X, Pan X, Cheng X, et al. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials. Int J Clin Pharm. 2015;37(6):1047–1056. DOI:10.1007/s11096-015-0151-y
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(19):1868. DOI:10.1056/NEJMc1503150
   PubMed Web of Science ®Google Scholar
• Vandetanib: too dangerous in medullary thyroid cancer. Prescrire Int. 2012;21(131):233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23185843. Accessed July 14, 2014. ​
   PubMedGoogle Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–2330. DOI:10.1200/JCO.2009.25.0068
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–1051. DOI:10.1111/j.1365-2133.2009.09290.x
   PubMed Web of Science ®Google Scholar
• Belum VR, Serna-Tamayo C, Wu S, et al. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2015. DOI:10.1111/ced.12694
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Brose MS. Sorafenib-related hand-foot skin reaction improves, not worsens, with continued treatment. Clin Cancer Res. 2009;15(24):7749. DOI:10.1158/1078-0432.CCR-09-1190
   PubMed Web of Science ®Google Scholar
• Senapati J, Devasia AJ, Ganapule A, et al. Sorafenib induced hand foot skin rash in FLT3 ITD mutated acute myeloid leukemia-a case report and review of literature. Mediterr J Hematol Infect Dis. 2014;6(1):e2014016. DOI:10.4084/MJHID.2014.016
   PubMedGoogle Scholar
• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107–119. DOI:10.1007/s11523-009-0114-0
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Ciccolini K, Kloos RT, et al. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid. 2014;24(9):1329–1340. DOI:10.1089/thy.2013.0700
   PubMed Web of Science ®Google Scholar
• Brose MS, Frenette CT, Keefe SM, et al. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol. 2014;41(Suppl 2):S1–S16. DOI:10.1053/j.seminoncol.2014.01.001
   PubMedGoogle Scholar
• Melosky B. Supportive care treatments for toxicities of anti-EGFR and other targeted agents. Curr Oncol. 2012;19(0):S59–63. DOI:10.3747/co.19.1054
   Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905. DOI:10.1016/S1470-2045(12)70335-2
   PubMed Web of Science ®Google Scholar
• Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care. 2013;7(2):162–167. DOI:10.1097/SPC.0b013e32835ec861
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11(10):962–972. DOI:10.1016/S1470-2045(10)70203-5
   PubMed Web of Science ®Google Scholar
• Qi W-X, Sun Y-J, Tang L-N, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2014;89(3):394–403. DOI:10.1016/j.critrevonc.2013.10.002
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn. 2010;37(4):347–363. DOI:10.1007/s10928-010-9164-2
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Gupta A, Shumaker R, et al. Model-based treatment optimization of a novel VEGFR inhibitor. Br J Clin Pharmacol. 2012;74(2):315–326. DOI:10.1111/j.1365-2125.2012.04197.x
   PubMed Web of Science ®Google Scholar
• Granito A, Marinelli S, Negrini G, et al. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol. 2016;9(2):240–249. DOI:10.1177/1756283X15618129
   PubMed Web of Science ®Google Scholar
• Hamnvik O-PR, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–319. DOI:10.1002/cncr.28972
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16. DOI:10.3109/08037051.2014.868629
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38:693–710. DOI:10.1007/s40264-015-0300-1
   PubMed Web of Science ®Google Scholar
• Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT Interval). Drug Saf. 2013;36(5):295–316. DOI:10.1007/s40264-013-0047-5
   PubMed Web of Science ®Google Scholar
• Qi W-X, Shen Z, Tang L-N YY. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol. 2014;78(4):748–762. DOI:10.1111/bcp.12387
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112(2):296–305. DOI:10.1038/bjc.2014.564
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Siqueira DR, et al. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol. 2013;168(6):K51–4. DOI:10.1530/EJE-13-0015
   Web of Science ®Google Scholar
• Toubert M-E, Vercellino L, Faugeron I, et al. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid. 2011;21(4):451–454. DOI:10.1089/thy.2010.0270
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7(2):e30353. DOI:10.1371/journal.pone.0030353
   PubMed Web of Science ®Google Scholar
• Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol. 2014;73:1109–1117. DOI:10.1007/s00280-014-2444-6
   PubMed Web of Science ®Google Scholar
• Grande E, Kreissl MC, Filetti S, et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther. 2013;30(11):945–966. DOI:10.1007/s12325-013-0069-5
   PubMed Web of Science ®Google Scholar
• Qi W-X, Shen Z, L-N T, et al. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71–82. DOI:10.1016/j.critrevonc.2014.04.004
   PubMed Web of Science ®Google Scholar
• Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer. 2013;132(12):2967–2974. DOI:10.1002/ijc.27979
   PubMed Web of Science ®Google Scholar
• Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707–716. DOI:10.1172/JCI17423
   PubMed Web of Science ®Google Scholar
• Zhang Z-F, Wang T, Liu L-H, et al. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One. 2014;9(3):e90135. DOI:10.1371/journal.pone.0090135
   Web of Science ®Google Scholar
• Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma. Cancer. 2011;117(3):534–544. DOI:10.1002/cncr.25422
   PubMed Web of Science ®Google Scholar
• Feldt S, Schüssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer. 2012;48(7):974–981. DOI:10.1016/j.ejca.2012.01.036
   PubMed Web of Science ®Google Scholar
• Lodish MB. Kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013;98(4):1333–1342. DOI:10.1210/jc.2012-4085
   PubMed Web of Science ®Google Scholar
• Yavuz S, Apolo AB, Kummar S, et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid. 2014;24(8):1223–1231. DOI:10.1089/thy.2013.0621
   PubMed Web of Science ®Google Scholar
• Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol. 2009;160(3):331–336. DOI:10.1530/EJE-08-0648
   PubMed Web of Science ®Google Scholar
• Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014;171:R91-R99. DOI:10.1530/EJE-14-0198
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf. 2014;1–11. DOI:10.1517/14740338.2014.913021.
   Web of Science ®Google Scholar
• Haraldsdottir S, Li Q, Villalona-Calero MA, et al. Case of sorafenib-induced thyroid storm. J Clin Oncol. 2013;31(16):e262–4. DOI:10.1200/JCO.2012.46.7142
   Google Scholar
• Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014;24(5):918–922. DOI:10.1089/thy.2012.0598
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173–180. DOI:10.1002/jso.20301
   PubMed Web of Science ®Google Scholar
• Marino R, Orlandi F, Arecco F, et al. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2014. DOI:10.1111/adj.12254
   PubMed Web of Science ®Google Scholar
• Krajewska J, Jarząb B. An internist’s approach to cancer diseases based on the model of thyroid cancer treated with tyrosine kinase inhibitors. Pol Arch Med Wewn. 2016;126(11):925–928. DOI:10.20452/pamw.3677
   PubMed Web of Science ®Google Scholar